参考文献
[1]Nieminen M S,Bohm M,Cowie M R,Drexler H,Filippatos G S,Jondeau G,et al.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Eur Heart J 2005;26(4):384-416.
[2]Dickstein K,Cohen-Solal A,Filippatos G,Mcmurray J J,Ponikowski P,Poole-Wilson P A,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine (ESICM).Eur Heart J 2008;29(19):2388-2442.
[3]Mcmurray J J,Adamopoulos S,Anker S D,Auricchio A,Bohm M,Dickstein K,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA)of the ESC.Eur Heart J 2012;33(14):1787-1847.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南[S].中华心血管病杂志(Chin),2010,38(3):195~208.
[5]Cotter G,Felker G M,Adams K F,Milo-Cotter O,O'Connor C M.The pathophysiology of acute heart failure--is it all about fluid accumulation? Am Heart J 2008;155(1):9-18.
[6]Schrier R W.Body fluid volume regulation in health and disease: a unifying hypothesis.Ann Intern Med 1990;113(2):155-159.
[7]Schrier R W.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure,nephrotic syndrome,cirrhosis,and pregnancy(2).N Engl J Med 1988;319(17):1127-1134.
[8]Schrier R W.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure,nephrotic syndrome,cirrhosis,and pregnancy(1).N Engl J Med 1988;319(16):1065-1072.
[9]Lepage S.Acute decompensated heart failure.Can J Cardiol 2008;24 Suppl B:6B-8B.
[10]Mann D L.Mechanisms and models in heart failure: A combinatorial approach.Circulation 1999;100(9):999-1008.
[11]Packer M.How should physicians view heart failure?The philosophical and physiological evolution of three conceptual models of the disease.Am J Cardiol 1993;71(9):3C-11C.
[12]Mentz R J,Kjeldsen K,Rossi G P,Voors A A,Cleland J G,Anker S D,et al.Decongestion in acute heart failure.Eur J Heart Fail 2014;16(5):471-482.
[13]Cotter G,Metra M,Milo-Cotter O,Dittrich H C,Gheorghiade M.Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation.Eur J Heart Fail 2008;10(2):165-169.
[14]Verwey HF,S.M,Sweeney R.Patients symptoms and device based activity for decompensated versus nondecompensated heart failure patients.J Card Fail 2005(12):170.
[15]Lewin J,Ledwidge M,O'Loughlin C,Mcnally C,Mcdonald K.Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005;7(6):953-957.
[16]Gheorghiade M,Abraham W T,Albert N M,Greenberg B H,O'Connor C M,She L,et al.Systolic blood pressure at admission,clinical characteristics,and outcomes in patients hospitalized with acute heart failure.Jama 2006;296(18):2217-2226.
[17]Milo-Cotter O,Adams K F,O'Connor C M,Uriel N,Kaluski E,Felker G M,et al.Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? Eur J Heart Fail 2007;9(2):178-183.
[18]Kaluski E,Kobrin I,Zimlichman R,Marmor A,Krakov O,Milo O,et al.RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edema: a prospective,multicenter,double-blind,placebo-controlled study.J Am Coll Cardiol 2003;41(2):204-210.
[19]Balmain S,Padmanabhan N,Ferrell W R,Morton J J,Mcmurray J J.Differences in arterial compliance,microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function.Eur J Heart Fail 2007;9(9):865-871.
[20]Cotter G,Metzkor E,Kaluski E,Faigenberg Z,Miller R,Simovitz A,et al.Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema.Lancet 1998;351(9100):389-393.
[21]Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.Jama 2002;287(12):1531-1540.
[22]Wakai A,Mccabe A,Kidney R,Brooks S C,Seupaul R A,Diercks D B,et al.Nitrates for acute heart failure syndromes.Cochrane Database Syst Rev 2013;8:D5151.
[23]Shirakabe A,Hata N,Kobayashi N,Shinada T,Tomita K,Tsurumi M,et al.Clinical significance of acid-base balance in an emergency setting in patients with acute heart failure.J Cardiol 2012;60(4):288-294.
[24]Felker G M,Lee K L,Bull D A,Redfield M M,Stevenson L W,Goldsmith S R,et al.Diuretic strategies in patients with acute decompensated heart failure.N Engl J Med 2011;364(9):797-805.
[25]Bart B A,Goldsmith S R,Lee K L,Givertz M M,O'Connor C M,Bull D A,et al.Ultrafiltration in decompensated heart failure with cardiorenal syndrome.N Engl J Med 2012;367 (24):2296-2304.
[26]Francis G S,Benedict C,Johnstone D E,Kirlin P C,Nicklas J,Liang C S,et al.Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure.A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation 1990;82(5):1724-1729.
[27]Metra M,Davison B,Bettari L,Sun H,Edwards C,Lazzarini V,et al.Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function.Circ Heart Fail 2012;5(1):54-62.
[28]O'Connor C M,Starling R C,Hernandez A F,Armstrong P W,Dickstein K,Hasselblad V,et al.Effect of nesiritide in patients with acute decompensated heart failure.N Engl J Med 2011;365(1):32-43.
[29]Gottlieb S S,Stebbins A,Voors A A,Hasselblad V,Ezekowitz J A,Califf R M,et al.Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).J Am Coll Cardiol 2013;62(13):1177-1183.
[30]Givertz M M,Teerlink J R,Albert N M,Westlake C C,Collins S P,Colvin-Adams M,et al.Acute decompensated heart failure: update on new and emerging evidence and directions for future research.J Card Fail 2013;19(6):371-389.
[31]Costanzo M R,Guglin M E,Saltzberg M T,Jessup M L,Bart B A,Teerlink J R,et al.Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.J Am Coll Cardiol 2007;49(6):675-683.
[32]Konstam M A,Gheorghiade M,Burnett J J,Grinfeld L,Maggioni A P,Swedberg K,et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.Jama 2007;297(12):1319-1331.
[33]Gheorghiade M,Konstam M A,Burnett J J,Grinfeld L,Maggioni A P,Swedberg K,et al.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.Jama 2007;297(12):1332-1343.(https://www.daowen.com)
[34]Leier C V,Dei C L,Metra M.Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia,hypokalemia,and hypomagnesemia.Am Heart J 1994;128(3):564-574.
[35]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[S].中华心血管病杂志(Chin)2014,42(2):98-122.
[36]Chaney E,Shaw A.Fluid Overload: Diagnosis and Management.,Karger,2010:164,46-53.
[37]Filippatos T D,Elisaf M S.Hyponatremia in patients with heart failure.World J Cardiol 2013;5(9):317-328.
[38]Balling L,Kistorp C,Schou M,Egstrup M,Gustafsson I,Goetze J P,et al.Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses.J Card Fail 2012;18(5):351-358.
[39]Rusinaru D,Tribouilloy C,Berry C,Richards A M,Whalley G A,Earle N,et al.Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(dagger): Meta-Analysis Global Group in Chronic heart failure(MAGGIC).Eur J Heart Fail 2012;14(10):1139-1146.
[40]Deubner N,Berliner D,Frey A,Guder G,Brenner S,Fenske W,et al.Dysnatraemia in heart failure.Eur J Heart Fail 2012;14(10):1147-1154.
[41]Spasovski G,Vanholder R,Allolio B,Annane D,Ball S,Bichet D,et al.Clinical practice guideline on diagnosis and treatment of hyponatraemia.Nephrol Dial Transplant 2014;29 Suppl 2:i1-i39.
[42]Parrinello G,Greene S J,Torres D,Alderman M,Bonventre J V,Di Pasquale P,et al.Water and Sodium in Heart Failure: A Spotlight on Congestion.Heart Fail Rev 2014.
[43]Mcmurray J J,Adamopoulos S,Anker S D,Auricchio A,Bohm M,Dickstein K,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA)of the ESC.Eur Heart J 2012;33(14):1787-1847.
[44]Konerman M C,Hummel S L.Sodium Restriction in Heart Failure: Benefit or Harm? Curr Treat Options Cardio Med 2014;16:286.
[45]Paterna S,Di Pasquale P,Parrinello G,Amato P,Cardinale A,Follone G,et al.Effects of highdose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus,in refractory congestive heart failure.Eur J Heart Fail 2000;2(3):305-313.
[46]Licata G,Di Pasquale P,Parrinello G,Cardinale A,Scandurra A,Follone G,et al.Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.Am Heart J 2003;145(3):459-466.
[47]Torres V E,Chapman A B,Devuyst O,Gansevoort R T,Grantham J J,Higashihara E,et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease.N Engl J Med 2012;367(25):2407-2418.
[48]Bielecka-Dabrowa A,Mikhailidis D P,Jones L,Rysz J,Aronow W S,Banach M.The meaning of hypokalemia in heart failure.Int J Cardiol 2012;158(1):12-17.
[49]Dei C L,Metra M,Leier C V.Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects.Clin Cardiol 1995;18(7):370-376.
[50]Bielecka-Dabrowa A,Mikhailidis D P,Jones L,Rysz J,Aronow W S,Banach M.The meaning of hypokalemia in heart failure.Int J Cardiol 2012;158(1):12-17.
[51]Nolan J,Batin P D,Andrews R,Lindsay S J,Brooksby P,Mullen M,et al.Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial(UK-heart).Circulation 1998;98(15):1510-1516.
[52]Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study[RALES]).Am J Cardiol 1996;78(8):902-907.
[53]Pitt B,Zannad F,Remme W J,Cody R,Castaigne A,Perez A,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators.N Engl J Med 1999;341(10):709-717.
[54]Pitt B,Bakris G,Ruilope L M,Dicarlo L,Mukherjee R.Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study(EPHESUS).Circulation 2008;118(16):1643-1650.
[55]Rossignol P,Menard J,Fay R,Gustafsson F,Pitt B,Zannad F.Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassiumsparing effects.Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study)substudy.J Am Coll Cardiol 2011;58(19):1958-1966.
[56]Ekundayo O J,Adamopoulos C,Ahmed M I,Pitt B,Young J B,Fleg J L,et al.Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study.Int J Cardiol 2010;141(2):167-174.
[57]Douban S,Brodsky M A,Whang D D,Whang R.Significance of magnesium in congestive heart failure.Am Heart J 1996;132(3):664-671.
[58]Gottlieb S S,Baruch L,Kukin M L,Bernstein J L,Fisher M L,Packer M.Prognostic importance of the serum magnesium concentration in patients with congestive heart failure.J Am Coll Cardiol 1990;16(4):827-831.
[59]Eichhorn E J,Tandon P K,Dibianco R,Timmis G C,Fenster P E,Shannon J,et al.Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.J Am Coll Cardiol 1993;21(3):634-640.
[60]Vaduganathan M,Greene S J,Ambrosy A P,Mentz R J,Fonarow G C,Zannad F,et al.Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure(from the EVEREST Trial).Am J Cardiol 2013;112(11):1763-1769.
[61]Pedersen C T,Kay G N,Kalman J,Borggrefe M,Della-Bella P,Dickfeld T,et al.EHRA/HRS/APHRS expert consensus on ventricular arrhythmias.Heart Rhythm 2014;11(10):e166-e196.
[62]Frangiosa A,De Santo L S,Anastasio P,De Santo N G.Acid-base balance in heart failure.J Nephrol 2006;19 Suppl 9:S115-S120.
[63]Milionis H J,Alexandrides G E,Liberopoulos E N,Bairaktari E T,Goudevenos J,Elisaf M S.Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure.Eur J Heart Fail 2002;4(2):167-173.
[64]Frangiosa A,De Santo L S,De Santo N G,Anastasio P,Favazzi P,Cirillo E,et al.Acid-base state in patients after cardiac transplantation.Am J Nephrol 2002;22(4):332-337.
[65]Douglas L.Mann,Douglas P.Zipes,Peter Libby,Bonow R O.Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.10,ed.Saunders;2014.
[66]余承高,白融,陈栋梁,黄勇.心脏电生理学基础与临床[M].武汉:华中科技大学出版社,2008:234-259.